JP2003514904A - ヒストン脱アセチル酵素の抑制剤 - Google Patents

ヒストン脱アセチル酵素の抑制剤

Info

Publication number
JP2003514904A
JP2003514904A JP2001540085A JP2001540085A JP2003514904A JP 2003514904 A JP2003514904 A JP 2003514904A JP 2001540085 A JP2001540085 A JP 2001540085A JP 2001540085 A JP2001540085 A JP 2001540085A JP 2003514904 A JP2003514904 A JP 2003514904A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkylene
group
inhibitor
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001540085A
Other languages
English (en)
Japanese (ja)
Inventor
ダニエル デローム
レジャン リュエル
リコ ラヴォイエ
カール ティボールト
エリー アブー−カリル
Original Assignee
メチルジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メチルジーン インコーポレイテッド filed Critical メチルジーン インコーポレイテッド
Publication of JP2003514904A publication Critical patent/JP2003514904A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001540085A 1999-11-23 2000-11-22 ヒストン脱アセチル酵素の抑制剤 Withdrawn JP2003514904A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16703599P 1999-11-23 1999-11-23
US60/167,035 1999-11-23
PCT/IB2000/001881 WO2001038322A1 (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009147470A Division JP5290065B2 (ja) 1999-11-23 2009-06-22 ヒストン脱アセチル化酵素の阻害剤

Publications (1)

Publication Number Publication Date
JP2003514904A true JP2003514904A (ja) 2003-04-22

Family

ID=22605679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001540085A Withdrawn JP2003514904A (ja) 1999-11-23 2000-11-22 ヒストン脱アセチル酵素の抑制剤
JP2009147470A Expired - Fee Related JP5290065B2 (ja) 1999-11-23 2009-06-22 ヒストン脱アセチル化酵素の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009147470A Expired - Fee Related JP5290065B2 (ja) 1999-11-23 2009-06-22 ヒストン脱アセチル化酵素の阻害剤

Country Status (11)

Country Link
US (3) US6541661B1 (https=)
EP (2) EP1233958B1 (https=)
JP (2) JP2003514904A (https=)
KR (4) KR20020070285A (https=)
AT (1) ATE514674T1 (https=)
AU (1) AU783504C (https=)
CA (1) CA2391952C (https=)
DK (1) DK1233958T3 (https=)
MX (1) MXPA02005196A (https=)
PT (1) PT1233958E (https=)
WO (1) WO2001038322A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511462A (ja) * 2000-09-29 2004-04-15 プロリフィクス　リミテッド Ｈｄａｃ阻害剤としてのスルホンアミド結合を含むカルバミン酸化合物
JP2007505942A (ja) * 2003-09-22 2007-03-15 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
JP2007508318A (ja) * 2003-10-09 2007-04-05 エートン ファーマ インコーポレーティッド チオフェンおよびベンゾチオフェンヒドロキサム酸誘導体
JP2007527902A (ja) * 2004-03-11 2007-10-04 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のアミド置換されたヒドロキシ−６−フェニルフェナントリジン
JP2008509075A (ja) * 2004-08-09 2008-03-27 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
JP2010523601A (ja) * 2007-04-09 2010-07-15 メシルジーン インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2010540426A (ja) * 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
JP2011510917A (ja) * 2008-01-29 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規ｎ−（２−アミノ−フェニル）−アミド誘導体
JP2011519966A (ja) * 2008-05-16 2011-07-14 エフ．ホフマン−ラ ロシュ アーゲー 新規なｎ−（２−アミノ−フェニル）−アクリルアミド
JP2012505872A (ja) * 2008-10-15 2012-03-08 ジェネリクス・（ユーケー）・リミテッド ボリノスタットの調製方法
US8754129B2 (en) 2008-11-26 2014-06-17 Generics [Uk] Limited Crystalline vorinostat form VI
JP2014514261A (ja) * 2011-02-28 2014-06-19 レプリジェン コーポレーション ヒストン脱アセチル化酵素阻害剤

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AU2001248701A1 (en) * 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1429765A2 (en) * 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
ATE458047T1 (de) 2002-03-07 2010-03-15 Univ Delaware Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
OA12793A (en) * 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
DE60326436D1 (en) * 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
KR20040093692A (ko) * 2002-03-13 2004-11-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
CA2479906C (en) * 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006503082A (ja) 2002-10-17 2006-01-26 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
US7465719B2 (en) 2003-01-17 2008-12-16 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
ITMI20030064A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
AU2003900587A0 (en) * 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
CA2518318A1 (en) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
SI1611088T1 (sl) 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
DE602004004665T2 (de) 2003-08-20 2008-01-03 Pharmacyclics, Inc., Sunnyvale Acetylenderivate als inhibitoren von histondeacetylase
KR100924737B1 (ko) 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
CN100546980C (zh) * 2003-09-22 2009-10-07 S*Bio私人有限公司 苯并咪唑衍生物:制备方法及医药应用
PL1673349T3 (pl) * 2003-09-22 2010-11-30 Mei Pharma Inc Pochodne benzimidazolu: wytwarzanie i zastosowania farmaceutyczne
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
DK1696898T3 (en) 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
EP1541549A1 (en) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
GB0402496D0 (en) * 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
WO2005121119A1 (en) 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Hydroxamates, their manufacture and use as pharmaceutical agents
US7423060B2 (en) 2004-06-14 2008-09-09 Hoffman-La Roche Inc. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
CA2566525A1 (en) 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Thiophene derivatives, their manufacture and use as pharmaceutical agents
JP2008505969A (ja) * 2004-07-12 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素の阻害剤
JP2008506776A (ja) * 2004-07-19 2008-03-06 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素阻害剤
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
ITMI20041869A1 (it) 2004-10-01 2005-01-01 Dac Srl Nuovi inibitori delle istone deacetilasi
ITMI20060621A1 (it) * 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
US8242175B2 (en) 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
EP1855111A4 (en) * 2005-03-02 2008-10-01 Astellas Pharma Inc NEW PD MARKER FOR HISTONE DEACETYLASE INHIBITOR
PT1861365E (pt) * 2005-03-15 2009-09-22 4Sc Ag N-sulfonilpirroles e a sua utilização como inibidores de histona-desacetilase
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
EP1868994B1 (en) * 2005-04-07 2011-05-25 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
CA2605110A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
AU2006240248A1 (en) * 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
AU2006240246A1 (en) 2005-04-20 2006-11-02 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN101189003B (zh) 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
CN101796055B (zh) 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
JP2008546793A (ja) 2005-06-24 2008-12-25 メルク エンド カムパニー インコーポレーテッド 修飾マロン酸誘導体
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
BRPI0617167B8 (pt) 2005-09-21 2021-05-25 Nycomed Gmbh sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
CN101287706A (zh) 2005-09-21 2008-10-15 尼科梅德有限责任公司 作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
KR20080091297A (ko) 2006-02-07 2008-10-09 아스텔라스세이야쿠 가부시키가이샤 Ｎ-히드록시아크릴아미드 화합물
AU2007214458C1 (en) * 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
JP2009528354A (ja) 2006-02-28 2009-08-06 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素のインヒビター
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
CA2654540C (en) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651681A1 (en) 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2007143822A1 (en) * 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008036046A1 (en) 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
JP2010513223A (ja) * 2006-12-15 2010-04-30 アステラス製薬株式会社 Ｎ−ヒドロキシアクリルアミド化合物
EP1973872A4 (en) * 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
RU2446796C2 (ru) 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
EP2993473A1 (en) 2007-01-30 2016-03-09 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
EP2124916A1 (en) * 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
US8008344B2 (en) 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
CA2700058A1 (en) 2007-09-19 2009-03-26 4Sc Ag Novel tetrahydrofusedpyridines
EP2209765A4 (en) 2007-10-22 2010-12-01 Orchid Res Lab Ltd HISTONE DEACETYLASE INHIBITORS
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US20110044952A1 (en) * 2007-11-27 2011-02-24 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
AU2009220942B2 (en) * 2008-03-07 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Methods of treatment employing prolonged continuous infusion of Belinostat
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
RU2515611C2 (ru) * 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
EP2330894B8 (en) 2008-09-03 2017-04-19 BioMarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CA2751777A1 (en) 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Novel ortho-aminoamides for the treatment of cancer
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
ES2473792T3 (es) 2009-04-03 2014-07-07 Naturewise Biotech & Medicals Corporation Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US9096518B2 (en) * 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2451790A4 (en) * 2009-07-07 2012-12-26 Anthem Biosciences Private Ltd INHIBITORS OF HISTONE DEACETYLASE
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
WO2011053876A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
KR200454001Y1 (ko) * 2009-11-03 2011-06-10 주식회사 한길테크 수위조절장치
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) * 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2012109527A2 (en) * 2011-02-10 2012-08-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US20140107166A1 (en) * 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
WO2014143666A1 (en) 2013-03-15 2014-09-18 Biomarin Pharmaceutical Inc. Hdac inhibitors
WO2014138989A1 (en) * 2013-03-15 2014-09-18 Methylgene Inc. Method and intermediates for the synthesis of hydroxamic acid compounds
CA2919996A1 (en) 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN105237444B (zh) * 2015-09-24 2018-03-30 沈阳药科大学 异羟肟酸类化合物及其制备方法和用途
CN106588943B (zh) 2015-10-19 2018-10-16 广东东阳光药业有限公司 一种egfr抑制剂的盐、晶型及其用途
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
AU2017280099A1 (en) * 2016-06-21 2019-01-17 The University Of Melbourne Activators of HIV latency
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN111072582B (zh) * 2018-10-18 2024-06-18 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202011537D0 (en) * 2020-07-24 2020-09-09 Univ Newcastle Compounds
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
EP4504165A1 (en) 2022-04-05 2025-02-12 Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
CN115304513A (zh) * 2022-08-25 2022-11-08 湖北科技学院 具有抗炎活性的查尔酮类衍生物及其合成方法和应用
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof
CN121248445A (zh) * 2025-09-29 2026-01-02 亳州学院 一种萘型查尔酮类化合物及其制备方法与应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012075A1 (fr) * 1991-12-10 1993-06-24 Shionogi & Co., Ltd. Derive d'acide hydroxamique a base de sulfonamide aromatique
JPH0748349A (ja) * 1993-02-17 1995-02-21 Chugai Pharmaceut Co Ltd インドリン−２−オン誘導体
JPH07502494A (ja) * 1991-10-04 1995-03-16 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 新規の有効な末端分化誘発剤およびその使用方法
WO1998025949A1 (en) * 1996-12-09 1998-06-18 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
JPH10182583A (ja) * 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
WO1998038859A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
WO1999041246A1 (en) * 1998-02-11 1999-08-19 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO1999051224A1 (de) * 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung
JPH11302173A (ja) * 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JP2003509343A (ja) * 1999-09-08 2003-03-11 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 新規クラスの細胞分化剤およびヒストンデアセチラーゼならびにそれらの使用方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB239863A (en) 1924-09-10 1925-11-19 Rachlis Dupin & Cie Sa Improvements in speed-changing system for cycle vehicles
US2279560A (en) 1940-05-08 1942-04-14 Du Pont Viscous hydrocarbon oil
US2279973A (en) 1940-05-08 1942-04-14 Du Pont Stabilization of organic substances
DE855866C (de) * 1950-12-16 1952-11-17 Schering Ag Verfahren zur Herstellung von o-Oxybenzhydroxamsaeuren
US2754286A (en) 1951-10-15 1956-07-10 Du Pont Aldehydes and their acetals
US4173577A (en) * 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
US4035376A (en) 1972-10-24 1977-07-12 Janssen Pharmaceutica N.V. Aroyl-substituted phenylacetic acid derivatives
BE826017R (fr) 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
JPS5436229A (en) * 1977-08-25 1979-03-16 Hokuriku Pharmaceutical Substituted acetohydroxam derivative
JPS5651144A (en) 1979-10-03 1981-05-08 Nippon Telegr & Teleph Corp <Ntt> Station address control system
JPS5651441A (en) 1979-10-05 1981-05-09 Nissan Chem Ind Ltd O- n-allyl-2,6-dichloroanilino phenylacetic acid derivative and its preparation
GB8531839D0 (en) 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
WO1986005779A1 (en) 1985-04-03 1986-10-09 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives
US4792560A (en) 1985-04-03 1988-12-20 Rorer Pharmaceutical Corporation Quinoline hydroxamates and their use as modulators of arachidonic acid metabolic pathways
GB8820185D0 (en) 1988-08-25 1988-09-28 Wellcome Found New medical use
US5364944A (en) 1989-10-27 1994-11-15 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid compounds
US5218124A (en) 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5028629A (en) 1990-03-28 1991-07-02 Eli Lilly And Company 5-Lipoxygenase inhibitors
JPH04217950A (ja) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
FR2677984B1 (fr) 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
AT397908B (de) 1991-12-23 1994-08-25 Zengerer Johannes Staubsauger
US5538777A (en) 1993-09-01 1996-07-23 Marley Mouldings Inc. Triple extruded frame profiles
WO1995013264A1 (en) 1993-11-08 1995-05-18 Terumo Kabushiki Kaisha Hydroxamic acid derivative and medicinal preparation containing the same
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
WO1997011366A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US5702811A (en) * 1995-10-20 1997-12-30 Ho; Kwok-Lun High performance abrasive articles containing abrasive grains and nonabrasive composite grains
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU731737B2 (en) 1996-10-16 2001-04-05 Wyeth Holdings Corporation The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2319680C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9813554A (pt) 1997-12-12 2001-07-24 Fuji Yakuhin Kogyo Kk Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase
WO2000056704A1 (en) * 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
HK1045501A1 (zh) 1999-05-12 2002-11-29 G.D. Searle & Co. 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物
AU3263201A (en) 1999-11-24 2001-06-04 University Of Hawaii Beam-steerer using reconfigurable pbg ground plane
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423744C (en) * 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US20040072770A1 (en) 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502494A (ja) * 1991-10-04 1995-03-16 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 新規の有効な末端分化誘発剤およびその使用方法
WO1993012075A1 (fr) * 1991-12-10 1993-06-24 Shionogi & Co., Ltd. Derive d'acide hydroxamique a base de sulfonamide aromatique
JPH0748349A (ja) * 1993-02-17 1995-02-21 Chugai Pharmaceut Co Ltd インドリン−２−オン誘導体
WO1998025949A1 (en) * 1996-12-09 1998-06-18 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
JPH10182583A (ja) * 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
WO1998038859A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
WO1999041246A1 (en) * 1998-02-11 1999-08-19 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO1999051224A1 (de) * 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylsäure-derivate mit antitumorwirkung
JPH11302173A (ja) * 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JP2003509343A (ja) * 1999-09-08 2003-03-11 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 新規クラスの細胞分化剤およびヒストンデアセチラーゼならびにそれらの使用方法

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009051845A (ja) * 2000-09-29 2009-03-12 Topotarget Uk Ltd Ｈｄａｃ阻害剤としてのスルホンアミド結合を含むカルバミン酸化合物
JP2004511462A (ja) * 2000-09-29 2004-04-15 プロリフィクス　リミテッド Ｈｄａｃ阻害剤としてのスルホンアミド結合を含むカルバミン酸化合物
JP2007505942A (ja) * 2003-09-22 2007-03-15 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
JP2007508318A (ja) * 2003-10-09 2007-04-05 エートン ファーマ インコーポレーティッド チオフェンおよびベンゾチオフェンヒドロキサム酸誘導体
JP4856623B2 (ja) * 2004-03-11 2012-01-18 フォーエスシー アクチエンゲゼルシャフト 新規のｎ−スルホニルピロール誘導体
JP2007527902A (ja) * 2004-03-11 2007-10-04 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のアミド置換されたヒドロキシ−６−フェニルフェナントリジン
JP2008509075A (ja) * 2004-08-09 2008-03-27 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
JP2010523601A (ja) * 2007-04-09 2010-07-15 メシルジーン インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2010540426A (ja) * 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
JP2011510917A (ja) * 2008-01-29 2011-04-07 エフ．ホフマン−ラ ロシュ アーゲー 新規ｎ−（２−アミノ−フェニル）−アミド誘導体
JP2011519966A (ja) * 2008-05-16 2011-07-14 エフ．ホフマン−ラ ロシュ アーゲー 新規なｎ−（２−アミノ−フェニル）−アクリルアミド
JP2012505872A (ja) * 2008-10-15 2012-03-08 ジェネリクス・（ユーケー）・リミテッド ボリノスタットの調製方法
US8883851B2 (en) 2008-10-15 2014-11-11 Generics [Uk] Limited Process for the preparation of vorinostat
US9162974B2 (en) 2008-10-15 2015-10-20 Generics (Uk) Limited Process for the preparation of vorinostat
US8754129B2 (en) 2008-11-26 2014-06-17 Generics [Uk] Limited Crystalline vorinostat form VI
JP2014514261A (ja) * 2011-02-28 2014-06-19 レプリジェン コーポレーション ヒストン脱アセチル化酵素阻害剤
JP2018012718A (ja) * 2011-02-28 2018-01-25 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
JP2019065037A (ja) * 2011-02-28 2019-04-25 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤

Also Published As

Publication number Publication date
EP1748046A2 (en) 2007-01-31
AU783504B2 (en) 2005-11-03
JP5290065B2 (ja) 2013-09-18
USRE39850E1 (en) 2007-09-18
CA2391952C (en) 2012-01-31
JP2010013443A (ja) 2010-01-21
EP1748046A3 (en) 2007-08-22
EP1233958B1 (en) 2011-06-29
KR20100035666A (ko) 2010-04-05
WO2001038322A1 (en) 2001-05-31
CA2391952A1 (en) 2001-05-31
KR20070053362A (ko) 2007-05-23
KR20020070285A (ko) 2002-09-05
KR101026205B1 (ko) 2011-03-31
ATE514674T1 (de) 2011-07-15
KR20090007495A (ko) 2009-01-16
AU1876801A (en) 2001-06-04
DK1233958T3 (da) 2011-10-17
EP1233958A1 (en) 2002-08-28
PT1233958E (pt) 2011-09-20
USRE43343E1 (en) 2012-05-01
AU783504C (en) 2006-08-03
US6541661B1 (en) 2003-04-01
MXPA02005196A (es) 2003-09-22

Similar Documents

Publication Publication Date Title
JP5290065B2 (ja) ヒストン脱アセチル化酵素の阻害剤
JP5554988B2 (ja) ヒストンデアセチラーゼの阻害剤
AU2007335216C1 (en) Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) Inhibitors of histone deacetylase and prodrugs thereof
US7868205B2 (en) Inhibitors of histone deacetylase
HK1095043A (en) Inhibitors of histone deacetylase
AU2006200456A1 (en) Inhibitors of histone deacetylase
ES2368033T3 (es) Inhibidores de histona desacetilasa.
EP1524262A1 (en) Inhibitors of histone deacetylase
HK1126769B (en) Benzamide derivatives as inhibitors of histone deacetylase

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090408

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091007

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091030

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101222

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110808